SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT02511288

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Liquid Biopsies in Patients With Advanced Non-small Cell Lung Cancer

The goal of this project is to characterize the genetic profile of patients with advanced stage IIIB/IV non-small cell lung cancer (NSCLC) using liquid biopsies

NCT02511288 Carcinoma, Non-Small-Cell Lung
MeSH: Carcinoma, Non-Small-Cell Lung
HPO: Non-small cell lung carcinoma


Primary Outcomes

Description: Technique: ddPCR + targeted NGF, whole exome sequencing

Measure: Identification of the genetic profile in advanced or metastatic NSCLC patients using liquid biopsies (circulating tumoral DNA)

Time: 5 years

Secondary Outcomes

Description: Techniques: ddPCR + targeted NGF, whole exome sequencing

Measure: Identification of genetic biomarkers (or molecular profiles) having a potential predictive value in the treatments response

Time: 5 years

Description: Techniques: ddPCR + targeted NGF, whole exome sequencing

Measure: Detection of the ALK and ROS1 genes translocations in the circulating DNA

Time: 5 years

Description: Correlation between mutated allelic fractions or expression's modification with the treatment response. Techniques: ddPCR + targeted NGF, whole exome sequencing

Measure: Evaluation of the liquid biopsies role in the tumoral monitoring

Time: 5 years

Description: Correlation between transcriptomic and genomic factors and response to immunotherapy. Techniques: ddPCR + targeted NGF, whole exome sequencing

Measure: Evaluation of genomic and transcriptomic factors detectable in the plasma, associated to the immunotherapy response

Time: 5 years

Description: Techniques: ddPCR + targeted NGF, whole exome sequencing

Measure: Evaluation of the spatial and temporal tumor heterogeneity under targeted therapy treatment

Time: 5 years

Description: Correlation between miRNAS expression in plasma and treatment's efficacy. Techniques: miRNAs profiling using HTG technology

Measure: Evaluation of the miRNAs' expression in plasma as an epigenetic factor associated to treatments response

Time: 5 years

Description: Single cell isolation technology

Measure: Circulating tumoral cells isolation and analysis to determine the role of non-genomic and/or phenotypic factors in the treatments response.

Time: 5 years

Description: Technique: ddPCR + targeted NGF, whole exome sequencing

Measure: Evaluation of the resistance mechanisms to targeted therapies

Time: 5 years

Time Perspective: Prospective

Cohort


There is one SNP

SNPs


1 T790M

It is presently used in routine for detecting the EGFR mutations at diagnosis as well as for searching EGFR T790M mutation for resistant patients. --- T790M ---



HPO Nodes


HPO:
Non-small cell lung carcinoma
Genes 3
TP53 TP53 BAP1